{
    "clinical_study": {
        "@rank": "18367", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "ANG1005 administered to bevacizumab-naive recurrent GBM patients"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "ANG1005 and possibly bevacizumab administered to bevacizumab-refractory recurrent GBM patients"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "ANG1005 administered to recurrent WHO Grade III anaplastic glioma"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells\n      in patients with high-grade glioma. Another purpose of this study is to assess the efficacy,\n      safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients."
        }, 
        "brief_title": "ANG1005 in Patients With Recurrent High-Grade Glioma", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glioma", 
            "Glioblastoma", 
            "Brain Tumor, Recurrent"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Glioblastoma", 
                "Glioma"
            ]
        }, 
        "detailed_description": {
            "textblock": "See above."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. \u2265 18 years old\n\n          2. GBM and GBM variants, WHO Grade III anaplastic glioma diagnosis confirmed\n\n          3. Radiologically confirmed recurrent and bi-dimensionally measurable disease per\n             Response Assessment in Neuro-Oncology (RANO) criteria\n\n          4. Neurologically stable\n\n          5. For bevacizumab-refractory patients, radiologic demonstration of tumor progression\n             during bevacizumab therapy\n\n          6. Karnofsky performance status (KPS) \u2265 70\n\n        Exclusion Criteria:\n\n          1. More than three relapses\n\n          2. Previous ANG1005/GRN1005 treatment\n\n          3. Radiotherapy within 3 months.\n\n          4. Therapy with bevacizumab within 4 weeks prior to screening for recurrent WHO grade\n             III anaplastic glioma patients (Arm 3)\n\n          5. Evidence of significant intracranial hemorrhage\n\n          6. Previous taxane treatment\n\n          7. Prior therapy with bevacizumab for bevacizumab-na\u00efve patients (Arm 1)\n\n          8. NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 Grade \u2265 2 neuropathy\n\n          9. Inadequate bone marrow reserve"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "83", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967810", 
            "org_study_id": "ANG1005-CLN-03"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2", 
                    "Arm 3"
                ], 
                "description": "ANG1005 at a starting dose of 650 mg/m2 by intravenous  infusion once every 3 weeks", 
                "intervention_name": "ANG1005", 
                "intervention_type": "Drug", 
                "other_name": "GRN1005"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "For patients enrolled in the bevacizumab-refractory in recurrent GBM (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "glioma", 
            "glioblastoma", 
            "brain cancer", 
            "brain tumor", 
            "recurrent"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "link": {
            "description": "A Phase I sudy of ANG1005 (GRN1005) in recurrent malignant glioma", 
            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23349317"
        }, 
        "location": [
            {
                "contact": {
                    "email": "jbrechlin@ucsd.edu", 
                    "last_name": "Joanne Brechlin, MBA, MPH", 
                    "phone": "858-822-5352"
                }, 
                "contact_backup": {
                    "email": "bdbrown@ucsd.edu", 
                    "last_name": "Bradley Brown", 
                    "phone": "858-822-5377"
                }, 
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92093-0698"
                    }, 
                    "name": "Moores UC San Diego Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Santosh Kesari, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "leanne.fountas@northwestern.edu", 
                    "last_name": "Leanne Fountas", 
                    "phone": "312-695-1342"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University"
                }, 
                "investigator": {
                    "last_name": "Priya Kumthekar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "karly_griffin@dfci.harvard.edu", 
                    "last_name": "Karly Griffin", 
                    "phone": "617-632-6749"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Patrick Wen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jmurphy7@bidmc.harvard.edu", 
                    "last_name": "Janlyn Murphy", 
                    "phone": "617-667-1832"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Patrick Wen, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Eric Wong, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "enunez2@mgh.harvard.edu", 
                    "last_name": "Edwin Nunez, CCRP", 
                    "phone": "617-643-4395"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Patrick Wen, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Tracy T Batchelor, MD, MPH", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "grzejkac@upmc.edu", 
                    "last_name": "Clare Grzejka, BSN, RN", 
                    "phone": "412-623-4891"
                }, 
                "contact_backup": {
                    "email": "vargasjaffema@upmc.edu", 
                    "last_name": "Melinda Vargas-Jaffe, BSN, RN", 
                    "phone": "412-235-1320"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15323"
                    }, 
                    "name": "UPMC Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Jan Drappatz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nolesc@uthscsa.edu", 
                    "last_name": "Cherie Noles", 
                    "phone": "210-450-5964"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Univeristy of Texas Health Science Center in San Antonio"
                }, 
                "investigator": {
                    "last_name": "Andrew Brenner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jjl4d@virginia.edu", 
                    "last_name": "Johanna Loomba, BS, CCRC", 
                    "phone": "434-924-5859"
                }, 
                "contact_backup": {
                    "email": "Mjt3c@virginia.edu", 
                    "last_name": "Monika Thielen", 
                    "phone": "434-243-9900"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22903"
                    }, 
                    "name": "Emily Couric Clinical Cancer Center"
                }, 
                "investigator": {
                    "last_name": "David Schiff, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma", 
        "overall_contact": {
            "email": "vburdusel@angiochem.com", 
            "last_name": "Veronica Burdusel, M.Sc.", 
            "phone": "514-788-7800", 
            "phone_ext": "206"
        }, 
        "overall_contact_backup": {
            "email": "blawrence@angiochem.com", 
            "last_name": "Betty Lawrence", 
            "phone": "514-788-7800", 
            "phone_ext": "205"
        }, 
        "overall_official": {
            "affiliation": "Angiochem Inc", 
            "last_name": "Jean-Paul Castaigne, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the radiologic ORR in bevacizumab-na\u00efve recurrent Glioblastoma multiforme (GBM) patients (Arm 1)and in recurrent anaplastic glioma WHO Grade III patients (Arm 3)", 
                "measure": "Objective Response Rate (ORR) (Arms 1 and 3)", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }, 
            {
                "description": "To determine the progression-free survival at 3 months (PFS3) in bevacizumab-refractory recurrent GBM patients (Arm 2)", 
                "measure": "PFS3 (Arm 2)", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967810"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the ORR in Arm 2", 
                "measure": "ORR in Arm 2", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }, 
            {
                "description": "To determine the number of patients without progression at 3, 6 and 12 months in Arms 1 and 3\nTo determine the number of patients without progression at 6 and 12 months in Arm 2", 
                "measure": "PFS at 3, 6 and 12 months", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }, 
            {
                "description": "To determine the median progression-free survival in each arm", 
                "measure": "Median PFS", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }, 
            {
                "description": "To determine the median duration of response in each arm", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }, 
            {
                "description": "To determine the median overall survival in each arm", 
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }, 
            {
                "description": "To determine the number of participants with adverse events", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Upon enrollment through end of study period (1 year after last patient is enrolled)"
            }, 
            {
                "description": "To determine the drug concentration and distribution in the blood (plasma)", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "At 0 h (pre-dose), at the end of infusion, at 2 and 4 hours post-dose on Day 1 of treatment cycles 1 and 3 (Week 1 and Week 9)"
            }
        ], 
        "source": "Angiochem Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Angiochem Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}